India Alzheimer’s Disease Drugs Market Report 2022 to 2030

India Alzheimer’s Disease Drugs Market Analysis

$ 3999

The India Alzheimer’s disease drugs market was valued at $280 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.42% from 2022 to 2030 and will reach $666 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Alkem Laboratories., Eli Lilly and Company, Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Pfizer.

ID: IN10INPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Nandini Shah

Buy Now

India Alzheimer’s Disease Drugs Market Executive Summary

The India Alzheimer’s Disease Drugs market was valued at $280 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.42% from 2022 to 2030 and will reach $666 Mn in 2030. Alzheimer's disease is a progressive neurological disorder that affects the brain, resulting in memory loss, cognitive decline, and behavioral changes. It is the most common cause of dementia, a group of disorders that cause a decline in mental ability and memory. As the population ages, the incidence of Alzheimer's disease is expected to increase, making it a significant public health concern. The development of new treatments and therapies, as well as increased awareness and support for patients and their families, is critical to managing the impact of Alzheimer's disease on individuals and society as a whole.

india alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

There has been a growing awareness of Alzheimer's disease in India in recent years, with more people becoming aware of the symptoms and seeking medical attention. This has led to an increase in the diagnosis rates of Alzheimer's disease, which in turn drives the demand for drugs. India has been investing heavily in healthcare infrastructure in recent years, with the government launching various initiatives to improve healthcare access and affordability. This has led to an increase in the availability of healthcare facilities and drugs, including Alzheimer's drugs, which is expected to drive market growth. The development of new drugs and therapies for Alzheimer's disease is a major driver of market growth. Pharmaceutical companies are investing heavily in research and development to develop new drugs and therapies for Alzheimer's disease, which is expected to drive market growth in the coming years. The Indian government has launched various initiatives to improve healthcare access and affordability, including the National Health Policy 2017 and the Ayushman Bharat Yojana. These initiatives are expected to drive market growth by increasing access to healthcare facilities and drugs, including Alzheimer's drugs.

Market Restraints

The success rate of Alzheimer’s Disease drug development remains low. According to a report by the Alzheimer’s Disease Drug Discovery Foundation, the failure rate for Alzheimer’s Disease drug candidates is approximately 99.6%, which leads to a significant financial burden on drug developers. Alzheimer’s Disease is a complex and multifactorial disease, which makes it challenging to develop effective treatments. The disease involves multiple pathological pathways, and a drug that targets one pathway may not be effective in treating the disease as a whole. Developing new drugs for Alzheimer’s Disease is a costly and time-consuming process. The long and complex clinical trial process, coupled with a high failure rate, drives up development costs and may discourage investment in research and development.

Competitive Landscape

Key Players

Sun Pharma
Cipla
Dr. Reddy's Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Alkem Laboratories Ltd.
Zydus
Biogen
Eisai Co.
Eli Lilly and Company
H. Lundbeck A/S
Johnson and Johnson
Merck & Co.
Novartis AG
Pfizer
Cadila
Lupin Limited

Healthcare Policies and Regulatory Landscape

The National Health Policy 2017 aims to provide universal health coverage and improve the quality of healthcare services in India. The policy outlines several strategies to achieve these goals, including increasing government spending on healthcare, strengthening healthcare infrastructure, and improving the availability of essential medicines.

The Ayushman Bharat Yojana is a government-funded health insurance scheme that provides financial protection for families in case of hospitalization. The scheme covers the cost of treatment, including drugs, for specific medical conditions, including Alzheimer's disease.

The DPCO is a government order that regulates the prices of essential medicines in India. The order aims to make essential medicines affordable and accessible to all, including drugs used for the treatment of Alzheimer's disease.

The government of India has launched the National Alzheimer's and Dementia Plan in 2019, which aims to improve the diagnosis, treatment, and management of Alzheimer's disease in India. The plan outlines several strategies, including increasing public awareness, improving healthcare infrastructure, and promoting research and development.

Reimbursement Scenario

In India, the majority of the population does not have health insurance, and out-of-pocket payments are the primary mode of payment for healthcare services, including drugs. This means that patients or their families bear the majority of the cost of Alzheimer's drugs. However, some insurance providers do offer coverage for Alzheimer's drugs, either as part of a comprehensive health insurance plan or as a standalone benefit. The coverage and reimbursement rates for Alzheimer's drugs vary widely among insurance providers and can range from partial to complete coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Billion)

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
Combination Drugs
Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Billion)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Route of Administration

Oral
Transdermal
Intravenous

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.